We provide our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages.
MVMD is building a world-class biotech company centred around the implementation and licensing of our patented Quicksome™ oral delivery technologies across the global nutraceutical, vaccine and pharmaceutical landscape.
MVMD's underlying Quicksome™ technology has been in development since 2010, initially incorporated into several commercial dietary supplement products. To date, we have 14 patents in our patent portfolio, 12 extensions and have filed over a dozen provisional patents with respect to our Quicksome™ technology.
Mountain Valley MD Strategy
We are working against leading consumer propositions that offer increased bioavailability with rapid onset across the $2 trillion USD nutraceutical, vaccine and pharmaceutical industries.
MVMD’s advanced desiccated liposome formulations provide transmucosal delivery benefits across leading drug and vaccine application categories, including nutraceutical applications such as pain management, energy, focus, weight management, sleep, anxiety, and more.
Our Quicksome™ technology is available to leading nutraceutical, vaccine and pharmaceutical companies for license across a broad spectrum of molecules that provide unprecedented value propositions across their businesses.
Our focus on strategic distribution and licensing partnerships in key markets will enable us to leverage our intellectual property, establish licensing agreements and monetize our IP rapidly.
Across our delivery sciences IP portfolio and R&D work, MVMD prioritizes investment opportunities on disruptive technologies for health and wellness applications.
Our management team brings together world-class leadership across mucosal delivery sciences, molecular research, IP and legal management, marketing, distribution and financial services.
“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”
“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”
“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”
“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”
“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”
“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”
“We believe Mountain Valley MD’s patented Quicksome™ technology revolutionizes drug and nutraceutical ingredient delivery for superior health outcomes by simultaneously addressing a multitude of key drug and nutraceutical product efficacy challenges, such as low bioavailability, high absorption variability and poor dosage control.”
“Many of the active ingredients contained in traditional pharmaceutical drugs and nutraceutical supplements are not well absorbed and suffer extensive degradation during first pass metabolism. We feel this is exactly the problem that Mountain Valley MD’s direct-to-mouth Quicksome™ technology solves, dramatically improving bioavailability of compounds that are traditionally heavily metabolized by MAO enzymes, glucuronidation and other conjugation processes”.
“We have an amazingly talented team that is working on solving some very advanced challenges in the health and wellness space. To date we have done research and development work with more than 60 molecules for a variety of nutraceutical and pharmaceutical applications, including drugs, vaccines, the emerging mushroom space and cannabinoids.”
“For me personally, the idea that our delivery technology could help dispense drugs such as insulin or deliver vaccines into the body through a rapid dissolve sublingual strip and eliminate the need for painful needle injections is truly game changing.”